Aprea Therapeutics, Inc. (NASDAQ:APRE) made its public debut Thursday morning, opening at $15.46 after being priced at $15 per share.
The shares are listed on the Nasdaq under the ticker symbol “APRE.”
Aprea Therapeutics is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53.
JPMorgan, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.
Related Links:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
